Proxy Biomedical is an indigenous Irish company focused on transatlantic research and development. The company is part of a vibrant life science cluster in Galway and is a leading innovator of the next-generation medical products using proprietary biomaterials technology.

Proxy Biomedical is focused on the research, development, and manufacturing of medical devices used in surgery, tissue engineering, and pharmacology. Experienced medical device professionals and project managers work within state-of-the-art facilities and provide a timely response to market driven clinical requirements. 

The company has produced tissue engineering biomaterials with unsurpassed biologic and mechanical properties that can be used to create a controlled extra cellular matrix (ECM) through guided tissue regeneration. Some of the products have been approved for clinical use and are being sold commercially, while other product platforms are in development. The tissue engineering biomaterial can be used independently or in combination with molecules, growth factors, cytokines or other factors.

Proxy Biomedical is focused on biomaterials for healthcare procedures that are increasingly being performed on a younger and more active patient population. This trend requires that biomaterial-based medical devices assist in the regeneration of tissue with full or partial restoration of the patient's quality of life. Tissue engineering is a field combining biomaterial research, molecular biology, chemistry, and medicine. Proxy Biomedical Limited has positioned itself as a partner in the design, development, and production of biomaterials in the converging field of tissue engineering.

"Proxy Biomedical looks forward to providing advanced biomaterials solutions to REMEDI, to address a range of clinical applications in the converging field of tissue engineering."                                    

Niall Rooney (BE, PhD), Orthopaedic Programme Manager, Proxy Biomedicals Ltd

For more information, visit www.proxybiomedical.com